Summary: Researchers developed an artificial lymph node that can train T-cells to recognize and kill cancer cells, potentially revolutionizing cancer treatment. This new method involves implanting a sac filled with immune components under the skin to boost the immune response against cancer.
The study demonstrated the artificial lymph node’s effectiveness in mice with melanoma and colon cancer. The approach could lead to fewer manufacturing steps compared to existing therapies and enhance the immune system’s ability to fight cancer.
Key Facts:
- The artificial lymph node uses hyaluronic acid and immune-stimulating molecules to train T-cells.
- In mice, the artificial lymph node improved survival rates and slowed cancer growth.
- This method could simplify cancer treatment by reducing the need for complex cell extraction and manipulation.
Source: Johns Hopkins Medicine
Johns Hopkins Medicine scientists say they have developed an artificial lymph node with the potential to treat cancer, according to a new study in mice and human cells.
The newly developed lymph node — a sac filled with immune system components — is implanted under the skin, and is designed to act like a learning hub and stimulator to teach immune system T-cells to recognize and kill cancer cells.
Details of the experiments are published recently online and in the June 6 issue of Advanced Materials.
Lymph nodes — tiny glands throughout the body, mainly in the neck, armpits and groin — are part of the immune systems of mammals, including mice and people. They number in the hundreds so that immune cells in one area of the body don’t have to travel far to alert the immune system to impending danger.
“They are a landing spot where T-cells, the immune system’s fighting cells, lay dormant, waiting to be activated to fight infections or other abnormal cells,” says Natalie Livingston, Ph.D., first author of the research and currently a postdoctoral researcher at Massachusetts General Hospital.
“Because cancers can trick T-cells into staying dormant, the artificial lymph node was designed to inform and activate T-cells that are injected alongside the lymph node.”
To create the artificial lymph node, the scientists used hyaluronic acid, a moisturizing substance commonly used in cosmetics and lotions and found naturally in the body’s skin and joints.
Because of its properties, hyaluronic acid is often used in biodegradable materials such as wound healing patches meant to be implanted or applied to the body. Among those properties, hyaluronic acid can connect with T-cells via a cell surface receptor.
Johns Hopkins scientists led by Jonathan Schneck, M.D., Ph.D., published research in 2019 showing that hyaluronic acid boosts T-cell activation.
For the current study, the Johns Hopkins team used hyaluronic acid as the scaffolding, or base, for their new lymph node, and added MHC (major histocompatibility complex) or HLA (human histocompatibility antigen) molecules, which rev up T-cells and other immune system components.
Then, they also added molecules and antigens common to cancer cells to “teach” T-cells what to look for.
“By adding different antibodies to the artificial lymph node, we have the ability to control what the T-cells are being activated to search for,” says Livingston.
The resulting artificial lymph node is about 150 microns in size, about twice the width of a human hair. It’s small enough to remain under the skin and large enough to avoid being swept away in the blood stream.
“An advantage to this approach over other cell-based therapies such as CAR-T is fewer manufacturing steps,” says Schneck, who is a professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine, director of the Johns Hopkins Center for Translational Immunoengineering, and a member of the Institute for Cell Engineering, Kimmel Cancer Center and Institute for Nanobiotechnology.
Current cell-based therapies require extracting T-cells from a patient, manipulating them outside of the body to recognize a particular type of cancer, and injecting them back into the patient.
“In our approach, we inject T-cells along with an artificial lymph node, and the T-cells get primed and educated by the artificial lymph node inside of the body. Then, the T-cells can travel anywhere to destroy cancer cells,” says Schneck, who led the research team, along with Hai-Quan Mao, Ph.D., director of Johns Hopkins’ Nanobiotechnology Institute.
Livingston, Schneck and the research team tested the artificial lymph node in mice that were implanted with either melanoma or colon cancers. Six days after the tumors were implanted, the mice received injections of the artificial lymph node and T-cells.
The Johns Hopkins team compared these mice with ones receiving the artificial lymph node alone, those receiving T-cells alone (which have not been activated by the artificial lymph node) and those receiving T-cells in combination with a class of immunotherapy drug called anti-PD-1.
Nine days later, mice with melanomas and colon cancers that received a combination of the artificial lymph node, T-cells and the anti-PD-1 drug had the best survival rates (three of the seven mice were still alive at 33 days), compared with other groups that only lived to about 26 days.
This group of mice also had the slowest cancer growth rate. It took between five and 10 days longer for their cancers to double in size than the other groups.
The scientists also found that the artificial lymph node attracted an influx of other immune cells and acts as an “immunologically active niche” to help to further stimulate the immune system. When T-cells were injected into the mice alongside the artificial lymph node, T-cell numbers grew as much as nine times more plentiful.
Livingston says the artificial lymph node approach is different from a cancer vaccine, which typically activates a dendritic cell, an immune system component that teaches T-cells what to search for.
People with cancer often develop malfunctioning dendritic cells, and the artificial lymph node skips the dendritic cell to directly activate T-cells.
The research team plans to conduct additional laboratory studies to add more immune signaling molecules to the lymph node and recruit more of the host’s immune cells to the artificial lymph node environment.
“We blended the disciplines of materials science and immunology to create a potential therapy that forms its own immunology community — a kind of living drug,” says Schneck.
The researchers have filed for a patent involving the technology described in their research.
Funding: Funding for the research was provided by the National Institutes of Health (R01EB029341, R21CA185819, P41EB028239, T32AI007417), the National Science Foundation, the Ruth L. Kirschstein Predoctoral Individual National Research Service Award (F31CA275271), the NIH Cancer Nanotechnology Training Center at the Johns Hopkins Institute for NanoBioTechnology, the National Science Foundation Graduate Research Fellowship, the ARCS Foundation, the Siebel Foundation, and the Natural Sciences and Engineering Research Council of Canada’s Postgraduate Scholarships – Doctoral Award.
Other Johns Hopkins researchers who contributed to the study are John Hickey, Hajin Sim, Sebastian Salathe, Joseph Choy, Jiayuan Kong, Aliyah Silver, Jessica Stelzel, Mary Omotoso, Shuyi Li, Worarat Chaisawangwong, Sayantika Roy, Emily Ariail, Mara Lanis, Pratibha Pradeep, Joan Glick Bieler, Savannah Est Witte, Elissa Leonard, Joshua Doloff and Jamie Spangler.
About this cancer research news
Author: Vanessa Wasta
Source: Johns Hopkins Medicine
Contact: Vanessa Wasta – Johns Hopkins Medicine
Image: The image is credited to Neuroscience News
Original Research: Open access.
“In Vivo Stimulation of Therapeutic Antigen-Specific T Cells in an Artificial Lymph Node Matrix” by Natalie Livingston et al. Advanced Materials
Abstract
In Vivo Stimulation of Therapeutic Antigen-Specific T Cells in an Artificial Lymph Node Matrix
T cells are critical mediators of antigen-specific immune responses and are common targets for immunotherapy. Biomaterial scaffolds have previously been used to stimulate antigen-presenting cells to elicit antigen-specific immune responses; however, structural and molecular features that directly stimulate and expand naïve, endogenous, tumor-specific T cells in vivo have not been defined.
Here, an artificial lymph node (aLN) matrix is created, which consists of an extracellular matrix hydrogel conjugated with peptide-loaded-MHC complex (Signal 1), the co-stimulatory signal anti-CD28 (Signal 2), and a tethered IL-2 (Signal 3), that can bypass challenges faced by other approaches to activate T cells in situ such as vaccines.
This dynamic immune-stimulating platform enables direct, in vivo antigen-specific CD8+ T cell stimulation, as well as recruitment and coordination of host immune cells, providing an immuno-stimulatory microenvironment for antigen-specific T cell activation and expansion.
Co-injecting the aLN with naïve, wild-type CD8+ T cells results in robust activation and expansion of tumor-targeted T cells that kill target cells and slow tumor growth in several distal tumor models.
The aLN platform induces potent in vivo antigen-specific CD8+ T cell stimulation without the need for ex vivo priming or expansion and enables in situ manipulation of antigen-specific responses for immunotherapies.
